You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》大和:药明生物(02269.HK)虽遭大股东减持 但对未来业务增长趋势仍乐观
阿思达克 04-27 11:34
药明生物(02269.HK)今早公布,获主要股东Biologics Holdings知会计划配售1.08亿股现有股份(占公司已发行股本2.56%),每股配售价为107元,较昨收市价114.8元折让6.79%共套115.56亿元,完成後对药明生物持股量降至17.44%。大和发表报告表示,在今轮配股减持交易之前,Biologics Holdings已进行了10轮配售旧股及4轮配售新股的交易。

大和认为,药明生物主要股东Biologics Holdings配股减持,相信是受到风险投资(VC)及私募股权投资(PE)基金所推动,因很多风险投资及私募股权投资基金曾参与了2015年身为中概股的药明康德(02359.HK)的私有化计划(药明康德其後分别在香港及内地挂牌),当时药明生物属药明康德的一部份,而该行称对药明生物的未来增长趋势仍然乐观。

该行重申对药明生物「买入」评级及目标价140元,指公司截至3月15日总体未交付订单共120亿美元,指药明生物属该行在中国医药研发生产外包(CXO)行业首选股,相信公司在行业属具防守性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account